AusperBio Therapeutics and Ausper Biopharma (jointly known as AusperBio) have completed participant enrolment in two Phase II studies evaluating AHB-137, an antisense oligonucleotide, for the functional cure of chronic hepatitis B (CHB).
The Phase II study AB-10-8007 is designed to examine AHB-137 injection along with either pegylated interferon α-2b or a hepatitis B vaccine in HBeAg-negative CHB participants who are receiving nucleos(t)ide analogue therapy. This open-label, randomised, multi-centre study aims to evaluate both safety and efficacy parameters.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
AB-10-8008, the Phase II study focuses on treatment-naïve CHB participants in a randomised, multicentre design.
AusperBio co-founder and CEO Dr Guofeng Cheng said: “Combination therapies have historically been a key to treating or curing chronic viral infections, including HIV and HCV.
“The AB-10-8007 study aims to combine AHB-137 with approved HBV treatments to further increase functional cure rates, while the AB-10-8008 study explores the potential to expand AHB-137 treatment to a broader patient population.
“Together, these studies could further establish AHB-137 as the potential backbone therapy for HBV functional cure. We look forward to sharing interim results at international conferences throughout 2026.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAHB-137 has been designed using the company’s technology platform, Med-Oligo ASO. The investigational medicine aims to achieve a functional cure for CHB.
The clinical development of this therapy has generated positive outcomes, which have been presented at conferences, including EASL, AASLD, and APASL.
AusperBio co-founder and CSO Dr Chris Yang said: “The completion of enrolment in these Phase II trials positions us well as we move into the pivotal Phase III study of AHB-137, which was recently approved in China. We are excited and committed to advancing new treatment options with the goal of bringing a functional cure to a broader population of patients living with HBV.”
